تحلیل اختیاری محصول
با اجازه شما، از تحلیلهای محدود و حریمخصوصیمحور استفاده میکنیم تا مسیرهای پژوهشی مؤثر را بشناسیم. از ردیاب تبلیغاتی یا بازپخش نشست استفاده نمیکنیم. این انتخاب را میتوانید در تنظیمات تغییر دهید. بخوانید سیاست حفظ حریم خصوصی.
Illumina, Inc.'s published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $39.1B | |
|---|---|---|
| Revenue (ttm) | 4.5B | |
| Net income (ttm) | 824M | |
| EPS (ttm) | $5.37 | |
| Shares out | 151M | |
| P/E (trailing) | 53.8x | |
| P/E (forward) | 40.3x | |
| Volume | 2,029,934 | |
| Beta | 1.42 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-01-02 | 2023-01-01 | 2023-12-31 | 2024-12-29 | 2025-12-28 | Trend |
| Revenue | $4.53B | $4.58B | $4.50B | $4.37B | $4.34B | -1.0% |
| Gross profit | $3.15B | $2.97B | $2.74B | $2.86B | $2.87B | -2.3% |
| Operating income | $-123.0M | $-4.18B | $-1.07B | $-833.0M | $807.0M | — |
| Net income | $762.0M | $-4.40B | $-1.16B | $-1.22B | $850.0M | +2.8% |
| EPS (diluted) | $4.90 | $-28.00 | $-7.34 | $-7.69 | $5.45 | +2.7% |
| EBITDA | $128.0M | $-3.79B | $-1.07B | $-725.0M | $1.46B | +83.7% |
| R&D | $1.19B | $1.32B | $1.35B | $1.17B | $967.0M | -5.0% |
| SG&A | $2.09B | $1.30B | $1.61B | $1.09B | $1.09B | -15.1% |
Recent company headlines from major financial publishers.
The modal base path reflects management's FY2026 guidance for reported revenue and operating margin. Clinical consumables expansion at mid-teens offsets mid-to-high single-digit research declines. This trajectory generates Fair value of $119.53, implying -53.9% return relative to $259.19.
In the Bull case, clinical sequencing expands rapidly across oncology and rare disease diagnostics, driving mid-teens clinical consumables growth and enabling FY2027 revenue to reach high single digits. Operating margins expand via high consumable pull-through, supporting Potential value of $146.73. Notably, even this optimistic outcome remains well below $259.19.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 9.3% | $122 | $124 | $127 | $129 | $132 |
| 9.8% | $119 | $121 | $123 | $125 | $127 |
| 10.3% | $116 | $118 | $120 | $121 | $124 |
| 10.8% | $114 | $115 | $117 | $118 | $120 |
| 11.3% | $111 | $113 | $114 | $115 | $117 |
Upcoming earnings date and setup when available.
رتبهای که نسخهٔ پژوهشی منتشرشدهٔ هر ماه داشت. رتبه قیمت در تاریخ تحلیل را با ارزش منصفانه مقایسه میکند و سابقهای از درستی یا نادرستی ارزیابی نیست.
| سال | دی | بهمن | اسفند | فروردین | اردیبهشت | خرداد | تیر | مرداد | شهریور | مهر | آبان | آذر |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
